



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/119666/>

Version: Accepted Version

Article:

Huang, DB, File, TM, Torres, A et al. (2017) A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens. *Clinical Therapeutics*, 39 (8). pp. 1706-1718. ISSN: 0149-2918

<https://doi.org/10.1016/j.clinthera.2017.07.007>

© 2017 Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

1 Table 3: Clinical cure rates at test of cure and mortality within Day 28 in all populations by
 2 treatment

	Iclaprim q12h (n=23)	Iclaprim q8h (n=24)	Vancomycin (n=23)
Clinical Cure at TOC			
ITT	17 (73.9%)	15 (62.5%)	12 (52.2%)
MITT	6 (75%)	4 (57.1%)	2 (33.3%)
CE	16 (84.2%)	13 (77%)	11 (73.3%)
Difference in Clinical Cure Rates (97.5% CI) versus vancomycin			
ITT	21.7% (-9.3%, 52.8%); p=0.13	10.3% (-21.9%, 42.5%); p=0.47	---
MITT	41.7% (-13.5%, 96.8%); p=0.12	23.8% (-36.3%, 84.0%); p=0.39	
CE	10.9% (-20.9%, 42.6%); p=0.43	3.1% (-31.3%, 37.6%); p=0.84	
Death Within Day 28 (ITT)	2 (8.7%)	3 (12.5%)	5 (21.7%)
Difference in Death Rates (95% CI) versus vancomycin	-13.0% (-33.5%, 7.4%)	-9.2% (-30.7%, 12.2%)	---

3
 4
 5
 6

7 Table 4: Safety Parameters by Treatment

8
9

Category	Iclaprim q12h (N=23)	Iclaprim q8h (N=24)	Vancomycin (N=23)
Death within 28 days from start of treatment	2 (8.7%)	3 (12.5%)	5 (21.7%)
Any drug-related TEAE	4 (17.4%)	3(12.5%)	7 (30.4%)
Any serious AE	5 (21.7%)	4 (16.7%)	10 (43.5%)
Discontinued medication due to AEs	0 (0.0%)	2 (8.3%)	3 (13.0%)
TEAE \geq 2 in any treatment arm assessed as related to study medication			
Thrombocythemia	0	1 (4.2%)	2 (8.7%)
Diarrhea	0	0	2 (8.7%)
Prolonged QTc	2 (8.7%)	0	0

10
11 TEAE=treatment emergent adverse event; AE= Adverse event; N=Total number of patients in
12 the population; SAE=serious adverse event